Heat Biologics, Inc. (HTBX): Price and Financial Metrics
GET POWR RATINGS... FREE!
HTBX Stock Price Chart Interactive Chart >
HTBX Price/Volume Stats
| Current price | $2.38 | 52-week high | $10.85 |
| Prev. close | $2.37 | 52-week low | $2.07 |
| Day low | $2.33 | Volume | 43,600 |
| Day high | $2.48 | Avg. volume | 171,558 |
| 50-day MA | $2.65 | Dividend yield | N/A |
| 200-day MA | $4.38 | Market Cap | 61.05M |
Heat Biologics, Inc. (HTBX) Company Bio
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.
Latest HTBX News From Around the Web
Below are the latest news stories about Heat Biologics Inc that investors may wish to consider to help them evaluate HTBX as an investment opportunity.
Morrisville firm targeting biothreats will leave the Nasdaq; new subsidiary scores $81M contractThe future subsidiary of a Triangle drugmaker has scored a federal contract potentially worth up to roughly $81 million. Meanwhile, the company is preparing to leave the Nasdaq for another stock exchange. |
Heat Biologics to move to NYSE from NasdaqHeat Biologics (HTBX) said it plans to change its listing to the NYSE American stock exchange from from the Nasdaq Capital Market.Heat expects to begin trading on NYSE under its |
Heat Biologics Announces Planned Transfer to the NYSE AmericanDURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announced today that it plans to change its listing from the Nasdaq Capital Market to the NYSE American stock exchange. “We are pleased to announce our listing on the NYSE American, a global leader in listings for a range of sectors, including life sciences and technology,” said Jeff |
Heat Biologics rises 10% as Elusys finalizes HHS contract for anthrax antitoxin AnthimElusys Therapeutics, which is being acquired by Heat Biologics < |
Heat Biologics' Merger Partner Elusys Finalizes HHS Contract For Its Anthrax TreatmentElusys Therapeutics Inc, the merger partner for Heat Biologics Inc (NASDAQ: HTBX), has finalized a contract with the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) for the continued supply of ANTHIM (obiltoxaximab), an anthrax antitoxin. The contract for ANTHIM consists of a base period of performance, valued at $50 million, which is fulfilled. The contract includes options valued at up to $31 million. If all optio |
HTBX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | -17.93% |
| 3-year | 36.00% |
| 5-year | -86.97% |
| YTD | N/A |
| 2022 | 0.00% |
| 2021 | -43.28% |
| 2020 | 61.20% |
| 2019 | -51.53% |
| 2018 | -74.41% |
Continue Researching HTBX
Here are a few links from around the web to help you further your research on Heat Biologics Inc's stock as an investment opportunity:Heat Biologics Inc (HTBX) Stock Price | Nasdaq
Heat Biologics Inc (HTBX) Stock Quote, History and News - Yahoo Finance
Heat Biologics Inc (HTBX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...